PDCD1 and neoplasm: Targeted therapies of HNSCC, for example epidermal growth factor receptor (EGFR) kinase inhibitors or monoclonal antibodies directed on PD-1 (programmed cell death-1) or vascular endothelial growth factor (VEGF), have been tested in such cases and represent an additional option in tumor spread control.